Compare COE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COE | CTMX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.1M | 596.2M |
| IPO Year | 2016 | 2015 |
| Metric | COE | CTMX |
|---|---|---|
| Price | $32.96 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 24.6K | ★ 2.9M |
| Earning Date | 12-08-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $81,215,000.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.49 |
| Revenue Growth | ★ 93.72 | N/A |
| 52 Week Low | $13.60 | $0.40 |
| 52 Week High | $56.13 | $4.62 |
| Indicator | COE | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 51.05 |
| Support Level | $32.03 | $3.86 |
| Resistance Level | $33.92 | $4.48 |
| Average True Range (ATR) | 1.57 | 0.26 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 24.63 | 43.57 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.